Oncology · Haematology
IMDC Risk Model (Metastatic RCC) calculator
Enter the published formula inputs below to calculate and interpret this score.
Clinical inputs
Result
Anyone can run this calculator. Sign in to save, favourite, or send the result.
0
IMDC favorable (0)
Band: IMDC favorable (0)
Interpretation. IMDC favorable (0)
Suggested management. Favorable IMDC risk.
IMDC Risk Model (Metastatic RCC): 0 — IMDC favorable (0). Interpretation: IMDC favorable (0) What to do: Favorable IMDC risk. Inputs: Karnofsky performance status <80%: false; Time from diagnosis to systemic therapy <1 year (+1): false; Hemoglobin < lower limit of normal (+1): false; Corrected calcium > ULN (+1): false; Neutrophils > ULN (+1): false; Platelets > ULN (+1): false Source: Heng DY et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. DOI: 10.1200/JCO.2008.21.4809. PMID: 19826129. Scope: KPS <80, diagnosis-to-treatment <1y, hemoglobin <LLN, calcium >ULN, neutrophil >ULN, platelet >ULN — 0 favorable, 1-2 intermediate, 3-6 poor. (2009)
Ruqelo is AI and can make mistakes. Check important information.
Clinical inputs
- Karnofsky performance status <80%
- Time from diagnosis to systemic therapy <1 year (+1)
- Hemoglobin < lower limit of normal (+1)
- Corrected calcium > ULN (+1)
- Neutrophils > ULN (+1)
- Platelets > ULN (+1)
Primary source
Heng DY et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. DOI: 10.1200/JCO.2008.21.4809. PMID: 19826129. Scope: KPS <80, diagnosis-to-treatment <1y, hemoglobin <LLN, calcium >ULN, neutrophil >ULN, platelet >ULN — 0 favorable, 1-2 intermediate, 3-6 poor. (2009)
View source